covid_cell_1_20

Pharmafile.com’s weekly COVID-19 news round-up

January 20, 2021
Research and Development

The past week has seen promising developments in the race to find treatments for COVID-19; Jubilant and The Wistar Institute …

stem_cell

Scientists in Scotland make breakthrough MND discovery

January 20, 2021
Research and Development motor neurone disease

Researchers in Scotland have made a discovery that could reverse the damage caused by motor neurone disease (MND). University of …

NICE approves lipid disorder drug Myalepta for NHS use

January 20, 2021
Research and Development Amryt Pharma, NICE

NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …

astrazeneca_sign_sky

EU approves breast cancer drug Enhertu

January 20, 2021
Research and Development AstraZeneca, Daiichi Sankyo

The EU has granted AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) conditional approval as a monotherapy for the treatment of …

Pfizer-BioNTech COVID-19 vaccine likely to protect against UK variant, study says

January 20, 2021
Research and Development COVID-19, Pfizer

The Pfizer-BioNTech COVID-19 vaccine is likely to protect against the coronavirus variant found in Britain, the latest research says. The …

img_4190-e1376666350337-web

MHRA grants Promising Innovative Medicine Designation to Sanofi’s RSV drug

January 19, 2021
Manufacturing and Production MHRA, Sanofi

The MHRA has granted a Promising Innovative Medicine (PIM) Designation to Sanofi’s nirsevimab, which is being investigated a passive immunisation …

NICE recommends cutting-edge lymphoma treatment for NHS use

January 19, 2021
Manufacturing and Production Cancer, NICE

NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …

covaxin

Bharat Biotech advises certain groups against taking its COVID-19 vaccine

January 19, 2021
Manufacturing and Production Bharat Biotech, COVID-19

India’s vaccine developer Bharat Biotech has advised a number of groups to avoid taking its homegrown COVID-19 vaccine, Covaxin. According …

Novartis’ Cosentyx available on NHS in Scotland

January 19, 2021
Manufacturing and Production Novartis

Novartis has announced that Cosentyx (secukinumab) 150mg is available in Scotland on the NHS, licensed for adults with active non-radiographic …

ConserV and Lawrence Livermore National Laboratory to collaborate on coronavirus vaccine

January 19, 2021
Manufacturing and Production COVID-19, ConserV Bioscience

ConserV Bioscience, a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and Lawrence …

jubilant

Jubilant and The Wistar Insitute collaborate on potential COVID-19 treatment

January 18, 2021
Sales and Marketing Jubilant Therapeutics

Jubilant Therapeutics, a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, has …

senior-woman-suffering-from-knee-pain-home_61573-2004

Theramex launches osteoporosis drug Livogiva in Europe

January 18, 2021
Sales and Marketing Theramex, osteoporosis

Theramex, a London-headquartered pharmaceutical company dedicated to women’s health, has launched osteoporosis medicine Livogiva to patients in Europe for the …

viiv

ViiV and Chelsea & Westminster Hospital launch digital service for HIV patients

January 18, 2021
Sales and Marketing HIV, ViiV Healthcare

Global specialist HIV company ViiV Healthcare and Chelsea and Westminster Hospital NHS Foundation Trust have launched a new service, Klick, …

pentagon-headquarters-us-department-of-defense-virginia

US Department of Defense selects Faron for $6.1m COVID-19 research funding

January 18, 2021
Sales and Marketing Faron Pharmaceuticals, US

The US Department of Defense (DoD) has selected Faron Pharmaceuticals’ HIBISCUS study to receive $6.1 million of funding from the …

janssen_latest_logo_on_sign

FDA approves Janssen’s AL amyloidosis drug

January 18, 2021
Sales and Marketing FDA, Janssen

The FDA has approved Janssen’s DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone …

top_10_image_2_9

Pharmafile.com’s top 10 news stories of the week

January 15, 2021
Medical Communications COVID-19

Pharmafile.com’s most popular stories this week include the use of two new, potentially life-saving treatments for on COVID-19 patients, and …

sartorius-fahnen-2020

RoosterBio and Sartorius collaborate to scale up cell and gene therapy manufacturing

January 15, 2021
Medical Communications RoosterBio, Sartorius

RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems, …

astrazeneca_sign_sky

AstraZeneca’s Imfinzi gets EU and UK approval for new dosing option

January 15, 2021
Medical Communications AstraZeneca, Cancer, Imfinzi

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU and the UK for an additional dosing option in locally advanced, …

alexion_sign2

Alexion pauses Phase III ULTOMIRIS COVID-19 trial enrolment

January 15, 2021
Medical Communications Alexion, COVID-19

Alexion has paused further enrolment in the global Phase III study of ULTOMIRIS (ravulizumab-cwvz) in adult COVID-19 patients requiring mechanical …

NICE recommends GSK’s ZEJULA for advanced ovarian cancer

January 15, 2021
Medical Communications Cancer, GlaxoSmithKline, NICE

NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade …

The Gateway to Local Adoption Series

Latest content